LENZ Therapeutics
LENZ

LENZ Therapeutics (LENZ) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Piper SandlerMaintainedNeutral$7.00 from $12.00Aug 12, 2026
HC Wainwright & Co.MaintainedBuy$38.00Jul 7, 2026
CitigroupMaintainedBuy$20.00 from $26.00May 13, 2026
Piper SandlerDowngradedOverweight → Neutral$12.00 from $39.00May 12, 2026
HC Wainwright & Co.MaintainedBuy$38.00 from $48.00May 12, 2026
HC Wainwright & Co.MaintainedBuy$48.00 from $56.00Apr 21, 2026
CitigroupMaintainedBuy$26.00 from $52.00Mar 26, 2026
B of A SecuritiesMaintainedBuy$29.00 from $35.00Mar 25, 2026
Raymond JamesMaintainedOutperform$50.00 from $40.00Oct 20, 2025
Piper SandlerMaintainedOverweight$67.00 from $51.00Oct 10, 2025
HC Wainwright & Co.MaintainedBuy$56.00 from $48.00Aug 1, 2025
CitigroupMaintainedBuy$52.00 from $49.00Aug 1, 2025
Raymond JamesMaintainedOutperform$40.00 from $39.00Jul 31, 2025
CitigroupMaintainedBuy$49.00 from $45.00Jul 31, 2025
HC Wainwright & Co.MaintainedBuy$48.00 from $38.00Jul 28, 2025
HC Wainwright & Co.MaintainedBuy$38.00May 8, 2025
HC Wainwright & Co.MaintainedBuy$38.00Apr 16, 2025
Piper SandlerMaintainedOverweight$51.00 from $38.00Apr 14, 2025
CitigroupMaintainedBuy$47.00 from $44.00Mar 20, 2025
HC Wainwright & Co.MaintainedBuy$38.00Nov 7, 2024

Frequently asked questions

  • What is the latest analyst rating on LENZ?

    On Aug 12, 2026, Piper Sandler maintained LENZ Therapeutics at Neutral with a price target of $7.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.